GNRH1 and neoplasm: There were no significant differences in age, BMI, number of pregnancies and deliveries, maximum tumor diameter, or multiplicity of leiomyoma growth among the four groups divided based on preoperative GnRH agonist treatment and MED12 mutation status (Kruskal–Wallis test with Dunn’s post hoc analysis).